SUMMARY
The proton-coupled folate transporter (PCFT; SLC46A1) is a proton-folate symporter that is abundantly expressed in solid tumors and normal tissues such as duodenum. The acidic pH optimum for PCFT is relevant to intestinal absorption of folates and could afford a means of selectively targeting tumors with novel cytotoxic antifolates. PCFT is a member of the major facilitator superfamily (MFS) of transporters. Since MFS members exist as homo-oligomers, we tested this for PCFT since such structures could be significant to PCFT mechanism and regulation. By transiently expressing PCFT in RFC-and PCFT-null HeLa (R1-11) cells and chemical cross-linking with 1,1-methanediyl bismethanethiosulfonate and Western blotting, PCFT species with molecular masses approximating those of the PCFT dimer and higher-order oligomers were detected. Blue native polyacrylamide gel electrophoresis identified PCFT dimer, trimer and tetramer forms. PCFT monomers with hemagglutininand His10-epitope tags were co-expressed in R1-11 cells, solubilized and bound to Ni affinity columns, establishing their physical associations. Co-expressing YPet and ECFP*-tagged PCFT monomers enabled transport and fluorescence energy transfer in plasma membranes of R1-11 cells. Combined wild-type (WT) and inactive mutant P425R PCFTs were targeted to the cell surface by surface biotinylation/Western blots and confocal microscopy, and functionally exhibited a "dominant-positive" phenotype, implying positive cooperativity between PCFT monomers and functional rescue of mutant by WT PCFT. Our results demonstrate the existence of PCFT homo-oligomers and imply their functional and regulatory impact. Better understanding of these higher-order PCFT structures may lead to therapeutic applications related to folate uptake in hereditary folate malabsorption, and delivery of PCFT-targeted chemotherapy drugs for cancer.
Folates are essential for cell growth and tissue regeneration. The biologic role of folate cofactors derives from their participation in onecarbon transfer reactions leading to nucleotide precursors, serine, and methionine (1) . Since mammalian cells cannot synthesize folates de novo, membrane transport of extracellular folates is essential. Three primary transport routes are involved in folate internalization, including the reduced folate carrier ( 1 RFC), the proton-coupled folate transporter (PCFT) and the folate receptors. These transporters differ in terms of mechanism, and each system typically plays a unique role in mediating folate transport across epithelia and into systemic tissues (2).
The human PCFT (hPCFT; SLC46A1) is a proton-folate symporter that functions optimally at acidic pH by coupling the downhill flow of protons to the uphill transport of folates (3) (4) (5) . The role of hPCFT in intestinal folate absorption was established by demonstrating loss-of-function mutations in hPCFT in patients with the rare autosomal inherited disorder, hereditary folate malabsorption (HFM) (5) . To date, 17 unique hPCFT mutations have been reported in ethnically varied kindreds (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . While proton-coupled, this transporter is also functional at more physiologic pH, at which it retains appreciable affinity for pemetrexed (16) , a newer antifolate currently approved for treating mesothelioma and nonsquamous, non-small cell lung cancer (17) (18) (19) . In addition to proximal small intestine, PCFT is expressed in other normal tissues such as liver and kidney which do not experience low pH conditions (2). In terms of cancer, a prominent low-pH transport route was identified in 29 of 32 human solid tumor cell lines (20) and abundant hPCFT transcripts were detected by real-time PCR in large cohort (n=53) of human tumor sublines from an assortment of lineages (21) .The interstitial pH of solid tumors is reportedly acidic (22, 23) , conditions under which hPCFT would provide an important route of cytotoxic antifolate uptake if expressed at sufficient levels. Indeed, results of our recent studies imply that hPCFT could offer a unique means for selectively targeting solid tumors with cytotoxic antifolates that are not substrates for the ubiquitously-expressed reduced folate carrier (RFC) (21, (24) (25) (26) .
Reflecting its biological and therapeutic importance, a number of studies have begun to explore key structural determinants of hPCFT function ( Figure 1 ). There are two N-glycosylation consensus sites (Asn58 and Asn68) in the hPCFT loop domain between transmembrane domains (TMDs) 1 and 2. Based on results with substituted cysteine-scanning mutagenesis of a Cys-less hPCFT and accessibilities to thiol-reactive agents (27) , and on studies of hemagglutinin (HA) epitope accessibilities to epitope-specific antibody (28, 29) , hPCFT has 12 TMDs with N-and Ctermini directed to the cytosol. Structurally and/or functionally important residues have been identified in hPCFT and include (with possible roles) Glu185 (required for proton coupling) (30) , His247 and Ser172 (modulate folate and proton access to a high affinity binding site) (31) , His281 (important for substrate binding) (31) , Arg376 (impacts proton and substrate binding) (12) , and Asp156 (contributes to PCFT protein stability) (13) (Figure 1 ). In addition, residues mapping to a well-conserved β-turn in a region between TMDs 2 and 3 (DXXGRR; positions 109-114) were implicated as functionally important (6, 8, 13, 32, 33) ( Figure 1 ). From loss of transport for R113C hPCFT, a model was proposed in which TMDs 1, 3, 4 and 6 form a hydrophobic binding pocket into which Arg113 protrudes (32) . However, this has not been experimentally validated.
Like RFC, PCFT belongs to the major facilitator superfamily (MFS) of transporters. Since numerous MFS proteins including LacS, AE1, GLUT1, TetA, and human RFC (hRFC) have been reported to exist as oligomers (e.g., dimers, tetramers, etc.) (34) (35) (36) (37) (38) (39) (40) , we decided to explore this important question for hPCFT given the potential mechanistic and regulatory ramifications of such structures. In this report, we use an assortment of powerful biochemical and molecular methods to assess the existence and potential functional impact of oligomeric hPCFT.
Generation of hPCFT and other plasmid constructs-An expression construct for deglycosylated hPCFT with a Myc epitope tag (dghPCFT ) and Gln substituted for Asn at positions 58 and 68 was generated by site-directed mutagenesis, using wild-type (WT) Myc-his6-tagged hPCFT (wthPCFT ) in pCDNA3.1 (24) To prepare fluorescent protein-tagged hPCFTs for the fluorescence resonance energy transfer (FRET) experiments (see below), YPetHis and ECFP*-His cDNAs optimized for mammalian codon expression of yellow and enhanced cyan fluorescent proteins, respectively, were provided by Dr. Tomoo Ohashi (Duke University Medical Center) (43). To generate monomeric YPet (mYPet) and ECFP* (mECFP*), Ala206 was substituted with lysine in both constructs, as described for other GFP variants (44) . To clone mYPet in the pCDNA3 vector (mYPet/pCDNA3), BamHI and EcoRI restriction sites were introduced 5' and 3', respectively, of the mYPet cDNA fragment. The mYPet cDNA fragment was digested with BamHI and EcoRI and cloned in pCDNA3 using these same sites. mECFP*/pCDNA3 was prepared using the same strategy with BamHI and EcoRV. To attach mYPet to the C-terminus of hPCFT (hPCFTmYPet), the hPCFT cDNA fragment was excised from the wthPCFT Myc construct by HindIII and BamHI digestions and inserted upstream of the mYPet cDNA in the mYPet/pCDNA3 construct using these same sites. An analogous strategy was used to attach mECFP* to the C-terminus of hPCFT (hPCFT-mECFP*), using the wthPCFT Myc and mECFP*/pCDNA3 constructs. Both hPCFTmYPet and hPCFT-mECFP* constructs included a two amino acid (GS) insertion between the hPCFT and the fluorescent protein tag. To attach mYPet to the N-terminus of hPCFT (mYPet-hPCFT), the hPCFT cDNA fragment was excised from the wthPCFT Myc /pCDNA3 construct by EcoRI and HpaI digestions and inserted downstream of the mYPet cDNA in mYPet/pCDNA3 at the EcoRI and HpaI sites. mYpet-hPCFT included a short (AEFHHTGKVDPH) linker between YPet and hPCFT. To generate a tandem construct in which mYPet and mECFP* (mYPet-mECFP*) are covalently linked head-to-tail for use as a positive control for the FRET experiments, the mYPet cDNA fragment was cut from mYPet/pCDNA3 and inserted upstream of the mECFP* cDNA in mECFP*/pCDNA3 between the HindIII and BamHI sites. The resulting construct included a small (GGS) linker between YPet and EGFP*.
A clinically relevant hPCFT mutant, P425R (6), was introduced into wt (Invitrogen) and purified on an Affi-Gel 10 peptide affinity column, as described by the manufacturer (BioRad, Richmond, CA). . FRET between YPet-and ECFP*-tagged hPCFT was assessed by calculating the sensitized emission (the YPet emission upon ECFP* excitation) from confocal donor and acceptor images, acquired separately using a laser-scanning confocal fluorescence microscope. All confocal microscopy work was performed in the Microscopy, Imaging and Cytometry Resources Core at Wayne State University, School of Medicine. The imaging equipment consisted of a Leica TCS SP5MP confocal microscope system (Leica Microsystems, Heidelberg, Germany), equipped with an argon laser (maximum luminous power at the focal plane is less than 30 mW) with 458 nm and 514 nm lines. ECFP* fluorescence protein was excited using the optimized donor excitation with the 458 nm laser line. Spectral detection bandwidth of the Leica SP5 channels was set up to balance minimal crosstalk with optimal collection efficiency. ECFP* fluorescence protein emission was detected between 460 and 490 nm; YPet was excited with a 514 nm argon laser, and emission was detected between 528 and 603 nm. FRET between ECFP* fluorescent protein and YPet was calculated using the FRET sensitized emission module of the Leica confocal software (LCS 2. ) hPCFT constructs were performed so as to identify hPCFT monomer expression and localization. After 48 h, cells were fixed with 3.3% paraformaldehyde (in PBS), permeabilized with 0.1% Triton X-100 (in PBS), and stained with primary antibodies, followed by incubation with secondary antibodies (49 H]Mtx (0.5 µM) was measured over 2 min at 37 °C in 60-mm dishes in 4-morphilinopropane sulfonic (MES)-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , and 5 mM glucose) at pH 5.5, as described (24) . Levels of intracellular radioactivity were expressed as pmol/mg of protein, calculated from direct measurements of radioactivity and protein contents (50) of the cell homogenates.
Protein association study with Ni
To systematically determine the impact of co-expressing WT with inactive P425R hPCFT, R1-11 cells were transfected with plasmids encoding wtPCFT sulfo-NHS-SS-biotin, after which biotinylated cell surface proteins were isolated on immobilized avidin, eluted and analyzed by SDS-PAGE and Western blots following deglycosylation with N-glycosidase F. Deglycosylated WT and P425R proteins were resolved (molecular masses differ by ~3.2 kDa), thus permitting quantification on Western blots with anti-HA antibody. hPCFT transport activities in excess of the low residual level for P425R were plotted against the fraction of WT hPCFT to total hPCFT forms (WT plus mutant). If hPCFT monomers function independently (i.e., monomeric hPCFT is the "minimal functional unit"), transport activity should closely reflect the amounts of WT hPCFT and increase linearly with increasing ratios of WT to total surface hPCFT forms (34, (51) (52) (53) (54) . However, if there is functional interaction between hPCFT monomers, total transport activity should increase or decrease quadratically with the increasing fraction of active hPCFT. These methods are completely analogous to those previously described for numerous other oligomeric transporters including hRFC (34, (51) (52) (53) (54) .
RESULTS

Identification of higher-order hPCFT structures with a bifunctional thiol-reactive cross-linker, MTS-1-MTS.
hPCFT has 7 cysteines (Cys21, Cys66, Cys151, Cys229, Cys298, Cys328, and Cys397) including 3 in the TMDs (Cys151, Cys229, and Cys397), 2 in intracellular loop domains (Cys21 and Cys328), and 2 in extracellular loop domains (Cys66 and Cys298) (Figure 1 ). To begin to examine the possibility of whether hPCFT exists as a higher-order oligomeric complex, we used an intermediate length (3Å) methane thiosulfonate bifunctional cross-linker, MTS-1-MTS, capable of cross-linking vicinal Cys residues. The experimental design involved transfecting hPCFT-null R1-11 cells with a functional (~60% of WT) Myc-His6-tagged hPCFT construct (dghPCFT ) in which the N-glycosylation consensus sites at Asn58 and Asn68 were mutated to Gln (to avoid complications of N-glycosylation in data analysis), then treating the transfectants with MTS-1-MTS to cross-link vicinal thiols. Following cross-linking, plasma membranes were prepared and membrane proteins were analyzed by SDS-PAGE and Western blotting with hPCFT-specific antibody.
While the predicted molecular mass of hPCFT is 52.8 kDa, non-cross-linked dghPCFT with non-hPCFT proteins. However, their molecular masses relative to that for monomeric dghPCFT are entirely consistent with their identities as higher-order hPCFT homo-oligomers (dimer, tetramer, etc.). Accordingly, these results demonstrate the feasibility of the existence of homo-oligomeric hPCFT.
Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) of dg
FLAG hPCFT . BN-PAGE has been used extensively to study multi-protein complexes including oligomeric structures of membrane proteins (55) . BN-PAGE uses CB G-250 which binds non-specifically to all proteins and is itself negatively charged. Since CB does not act as a detergent, BN-PAGE preserves oligomeric protein structures, while offering a higher resolution than other separation techniques such as gel filtration or sucrose density ultracentrifugation that are commonly used to determine molecular sizes and the relative abundances of oligomeric proteins (56) was not statistically significantly different from that measured when both constructs were transfected together) ( Figure  4A ).
To confirm plasma membrane targeting of the wthPCFT were targeted to the cell surface ( Figure 4B, lanes 2-4) . Due to marked differences in sensitivity of detection of low levels of surface hPCFT with anti-His6 and anti-HA antibodies, the major ~45 kDa unglycosylated hPCFT forms were most obvious when the blot was probed with anti-His6 antibody, although low levels of higher molecular mass glycosylated forms could be discerned. Detection with the anti-FLAG antibody was even less effective for these analyses (not shown). With anti-HA antibody, both the unglycosylated and glycosylated species were detected. Surface expression of wthPCFT and wthPCFT HA were expressed at the cell surface either singly or in combination, consistent with our surface biotinylation results, although there was some staining of intracellular structures, as previously reported (24) . There was no staining of untransfected R1-11 cells (not shown).
To further confirm whether there is a direct association between hPCFT monomers, singly (wthPCFT and showed a distinct dosedependence ( Figure 6B, left panels, lanes 1-3) HA proteins strongly argues that the association between hPCFT monomers is highly specific.
FRET analysis of mECFP*-and mYPet-tagged PCFT in situ.
FRET is a non-invasive technique designed to monitor formation of multi-protein or homo-oligomeric complexes in living cells, thus complementing biochemical approaches for studying protein oligomerization. Typically, fluorescent-tagged proteins with overlapping emission and excitation spectra (e.g., CFP and YFP) are co-expressed in cells and fluorescence is monitored at the emission wavelength for the acceptor fluorochrome (58) . To adapt this approach to studies of hPCFT oligomerization, it was necessary to first generate "monomeric" YPet and ECFP* forms (see Experimental Procedures) to eliminate potential interference resulting from oligomerization of the fluorescence proteins (43,44,59). To generate monomeric forms of YPet and ECFP*, Ala206 was replaced with lysine (44) . A positive control (mYPet-mECFP*) was also prepared in which mYPet was covalently linked "head-to-tail" to mECFP* ( Figure 7A , upper panel). To confirm their expression, the monomeric and fused YPet and ECFP* constructs were initially transfected into another HeLa subline (R5) and analyzed on Westerns with GFP antibody capable of reacting with YPet and ECFP* proteins. As shown in Figure 7A (lower panel), all fluorescent proteins expressed well and all showed the expected molecular masses (27.4 kDa for mYPet, 27.3 kDa for mECFP* and 55 kDa for mYPet-mECFP*) on Western blots.
To tag hPCFT, mYPet was fused to either the N-or C-terminus (termed mYPet-hPCFT and hPCFT-mYPet, respectively), and mECFP* was attached to the C-terminus of hPCFT (hPCFTmECFP*), as depicted in Figure 7A (upper panel). By combining the N-or C-terminal mYPet-tagged hPCFT with the hPCFT-mECFP* construct in a suitable co-expression model, it was possible to assess relative orientations of individual hPCFT monomers with respect to each other (i.e., "headto-head" or "head-to-tail") in putative oligomeric hPCFT complexes.
Initially, the individual hPCFT fusion constructs were transfected into R1-11 cells, then assayed for [ The Cterminal tagged constructs (both mYPet and mECFP*) showed substantially reduced signals with the hPCFT antibody, likely due to masking of the carboxyl-terminal peptide epitope resulting from its proximity to the fluorescent protein tag.
For FRET experiments, R1-11 HeLa cells were transfected with the various constructs both singly and in combination. Transfected DNAs were maintained constant with empty pCDNA3 plasmid. Transfections (including negative and positive controls) were as follows: (i) mYPet; (ii) mECFP*; (iii) mYPet plus mECFP*; (iv) mYPetmECFP*; (v) mYPet-hPCFT; (vi) hPCFT-mYPet; (vii) hPCFT-mECFP*; (viii) mYPet-hPCFT plus hPCFT-mECFP*; and (ix) hPCFT-mYPet plus hPCFT-mECFP*. FRET was measured with a confocal microscope as an increase in acceptor fluorescence resulting from donor excitation (i.e., sensitized emission FRET). Images collected in the FRET channel were corrected for fluorescence bleed-through. Representative FRET images are shown in Figure 7D . Calculated FRET values of both test samples and controls are represented using a pseudo color scale. Figure 7D were all significantly higher than that of the mYPet plus mECFP* negative control (0.08 ± 0.01), with P<0.0001 for mYPet-mECFP* and mYPet-hPCFT plus hPCFT-mECFP*, and P=0.0007 for hPCFT-mYPet plus hPCFTmECFP* (by paired t test, Figure 7C ).
These results strongly support the notion that hPCFT oligomers form in situ and that these protein-protein complexes localize to the plasma membrane of transfected R1-11 cells. Interestingly, the differences in FRET efficiencies for mYPethPCFT plus hPCFT-mECFP* (0.21 ± 0.02) and hPCFT-mYPet plus hPCFT-mECFP* (0.13 ± 0.01) were statistically significant (P=0.0003, by paired t test), suggesting that the association between monomeric hPCFT molecules shows a preferential (head-to-tail) orientation.
Co-expression of WT and mutant hPCFT monomers.
Co-expression of WT and inactive mutant protein monomers within the same cell is a powerful approach to study potential functionally important monomer interactions within homooligomeric membrane transporters (34, 40, 51, 53) . As long as transfection efficiencies are carefully controlled for (e.g., by co-transfections with a reporter gene construct), detection of a functionally dominant phenotype (negative-or positive-dominance) can provide powerful insights into the mechanistic or regulatory significance of these higher-order structures.
Among the inactive hPCFT mutants identified in patients with HFM (5-15), P425R in the loop-TMD 12 junction of the hPCFT protein (Figure 1) resulting from a C to G transition at position 1274 of the pcft coding sequence was of particular interest. When expressed in WT HeLa cells, P425R hPCFT, unlike most hPCFT mutants associated with HFM, was reported to show nominal transport function associated with at least some level of surface expression (6) . In hPCFTnull R1-11 cells, FLAG/Myc-His10-tagged P425R hPCFT showed ~5.1% of WT transport of [ Figure 4B , lanes 5 and 6), based on its low-level transport activity, this was insufficient to account for the disproportionate increase in net transport. Immunofluorescence staining of WT and mutant hPCFTs co-localizated primarily at the cell surface, although intracellular structures were also stained, as noted above ( Figure 5B, panels g-i) . There was a slight increased staining of Importantly, the transport data imply that the activity of the P425R mutant is at least partly restored via its association with a WT hPCFT monomer.
To examine this possibility systematically, we co-expressed wtPCFT (34, (51) (52) (53) (54) . However, if interactions (positive or negative) occur between WT and mutant monomers, the results should conform to a distinctly non-linear (quadratic) pattern, depending on whether the effect of WT/mutant co-association is dominant-positive or -negative and on the oligomerization state (dimer, trimer, etc.) (34, (51) (52) (53) (54) . Results with mutant and WT PCFT are shown in Figure 8 for 3 independent experiments (as mean values plus/minus SEMs) and clearly establish a strong positive deviation from linearity, suggesting cooperative interactions between hPCFT monomers that result in a net positive impact on carrier function, consistent with transport results in Figure 4A .
DISCUSSION
In this report, we used an assortment of powerful biochemical and molecular approaches to demonstrate the existence of hPCFT oligomers. (i) By protein cross-linking, oligomeric hPCFT appeared to predominate over monomeric carrier.
(ii) On BN-PAGE, dimeric hPCFT was the major species. (iii) HA and FLAG/His10 epitope-tagged hPCFT proteins co-localized to plasma membranes in transiently transfected R1-11 HeLa cells. (iv) By co-expression of His10-tagged and HA-tagged hPCFT proteins and Ni affinity chromatography, clear evidence of association between hPCFT monomers was obtained. Cofolding and specificity of this hPCFT monomer association was confirmed by mixing individually expressed hPCFT monomers prior to Ni chromatography and by co-expressing His10-tagged hPCFT with HA-tagged human ThTr1. Further, (v) FRET was detected at the cell surface for YPet and ECFP*-tagged hPCFTs, confirming that hPCFT monomer associations occurred in situ. Collectively, these results argue for a physical association between hPCFT monomers and the by guest on September 1, 2017 http://www.jbc.org/ Downloaded from existence of hPCFT oligomers at the cell surface. Although the involvement of associations of hPCFT with additional non-hPCFT proteins is also possible, the molecular masses of the higher-order hPCFT complexes by protein cross-linking or by BN-PAGE imply the existence of homooligomeric hPCFT.
The functional impact of these associations was strongly implied by evidence of a dominant positive phenotype when the inactive P425R hPCFT was co-expressed with WT hPCFT monomer. This appeared to involve co-folding and increased surface trafficking of P425R hPCFT to the cell surface, as reflected in increased surface levels of mutant hPCFT protein by surface biotinylation and Western blotting, and by indirect immunofluorescence and confocal microscopy. However, the net transport activity of combined P425R plus WT hPCFTs increased disproportionately to the levels of individual mutant/WT transport activities and to expression levels of WT and mutant hPCFT proteins. This was further tested by co-expressing P425R and WT hPCFTs in defined molar ratios, with levels of surface mutant and WT proteins measured by surface biotinylation and deglycosylation so that mutant and WT forms could be simultaneously detected on westerns. In these experiments, when net transport was plotted versus the fraction of surface WT hPCFT (34, (51) (52) (53) , a distinct positive non-linearity was detected, strongly implying functional "rescue" of the mutant monomer, independent of its intracellular trafficking but rather mediated allosterically via monomer interactions across the oligomer interface(s). Thus, functional cooperation between hPCFT monomers in facilitating transport of folate substrates appears likely.
Based on the "alternate access model" for secondary transporters such as Lac Y (60), we suggest an analogous reaction scheme for hPCFTmediated transport adapted from that of Unal et al. (30) which incorporates a functional impact of hPCFT oligomerization. The scheme shown in Figure 9 is based on a dimeric model for hPCFT suggested from our BN-PAGE results. We assume that both hPCFT monomers in homo-dimeric hPCFT undergo the transport cycle concurrently via 6 distinct stages. The scheme starts with an outward-facing unloaded hPCFT dimer composed of two WT monomers. The ordered binding of cotransported protons (step 1) and substrates (step 2) to both monomers triggers a conformational change that results in a membrane transition of hPCFT monomers from an outward to the inwardfacing state (step 3). This is followed by an ordered release of substrates (step 4) and protons (step 5) from both monomers into the cytoplasm, and finally, return of both unloaded monomers to their outward facing state to complete the transport cycle (step 6). Intrinsic to this model is a functional cooperativity between associated hPCFT monomers that effect substrate and proton binding and release in tandem. Based on our results, we hypothesize that the association of WT monomer with inactive P425R effects a conformational shift which activates the inactive mutant monomer, permitting loading of both substrates and protons (steps 1 and 2), coincident movement to assume an inward-facing state (step 3), and substrate and proton release (steps 4 and 5). While it is possible that other hPCFT mutants may show increased activity when oligomerized with WT PCFT, analogous to P425R, this is by no means obligatory. Indeed, based on the scheme depicted in Figure 9 , a dominant-negative phenotype can as easily be envisaged. This, along with additional studies of the structural determinants and mechanistic impact of hPCFT oligomerization will be the topics of future reports. Interestingly, the hPCFT primary structure includes GXXXG motifs in TMD 2 (amino acids 93-97) and TMD4 (amino acids 155-159), analogous to "dimerization motifs" implicated in the oligomerization of other amphipathic proteins (61, 62) .
Given the critical roles of hPCFT in intestinal absorption of dietary folates and of mutant hPCFT in HFM (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , and in the selective delivery of cytotoxic antifolates for targeting solid tumors (21, (24) (25) (26) , our findings of a functionally important oligomerization for hPCFT are particularly significant. For instance, in HFM, our findings may explain why all HFM patients thus far described have mutations in both pcft gene alleles, since loss of a single pcft allele on hPCFT function would likely not be detected (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Although hPCFT mutations in other diseases have not been reported, based on previous experiences with RFC and Mtx (63) , for hPCFT-selective antifolates (21, (24) (25) (26) , such mechanisms seem likely. Drawing from our results with P425R hPCFT, better understanding of the structural and regulatory determinants of hPCFT oligomerization may lead to novel approaches for therapeutically rescuing functionally impaired hPCFT mutants, perhaps with hPCFT peptidomimetics or small molecules. These topics are under active investigation in this laboratory and will be reported elsewhere.
HA, hemagglutinin; HFM, hereditary folate malabsorption; hPCFT, human proton-coupled folate transporter; hRFC, human reduced folate carrier; MES, 4-morphilinopropane sulfonic; MFS, major facilitator superfamily; MTS-1-MTS, 1,1-methanediyl bismethanethiosulfonate; Mtx, methotrexate; PCFT, proton-coupled folate transporter; PVDF, polyvinylenedifluoride; RFC, reduced folate carrier; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; sulfo-NHS-SS-biotin, sulfo-N-hydroxysuccinimide (NHS)-SS-biotin; TMD, transmembrane domain; WCL, whole cell lysates; WT, wild type. (lanes 4-10) . In the figure, a ~60 kDa protein was detected with hPCFT-specific antibody in cross-linked samples treated with DTT. This band was also detected in non-cross linked samples treated with reducing agents (e.g., DTT or 2-mercaptoethanol). While species a, b, and c were all detected when the blot shown was probed with cMyc antibody (not shown), the ~60 kDa was not. Abbreviation: NS, non-specific. Proteins were analyzed by SDS-PAGE and Western blots with detection using the Odyssey infrared imaging system, and GFP (primary, mouse polyclonal, Abcam) and IRDye800-conjugated (secondary) antibodies. Panel B, mYPet and mECFP* hPCFT fusion proteins were characterized for expression and transport function. Plasma membranes were prepared from non-and mock-pCDNA3 R1-11 cells and R1-11 cells transiently transfected with individual mYPet-hPCFT, hPCFT-mECFP*, and hPCFT-mYPet constructs. Plasma membrane preparations were isolated and separated by SDS-PAGE, followed by Western blot analysis and detection with the Odyssey infrared imaging system, using hPCFT-(upper panel) and GFP-(middle panel) specific antibodies, and IRDye800-conjugated secondary antibody. Transfected cells were also assayed for membrane transport (lower panel). [ Representative transport results are shown. Panel C, For FRET assays, mYPet plus mECFP* (negative control), mYPet-mECFP* tandem (positive control), mYPet-hPCFT plus hPCFT-mECFP*, and hPCFTmYPet plus hPCFT-mECFP* constructs were transiently transfected into R1-11 cells. R1-11 cells were also singly transfected with mYPet, mECFP*, mYPet-hPCFT, hPCFT-mECFP*, and hPCFT-mYPet constructs as controls (not shown). Forty eight hours post-transfection, mYPet and mECFP* images were acquired on a confocal microscope and total donor (mECFP*), total acceptor (mYPet), and sensitized FRET emissions (NET FRET) were calculated, as described under Experimental Procedures. FRET efficiency values from 15 separate cells (for each experimental sample and controls, as well) were used for statistical analyses. FRET efficiencies for both hPCFT dual transfections (mYPet-hPCFT plus hPCFTmECFP*, and hPCFT-mYPet plus hPCFT-mECFP*) were significantly higher than that for the negative control (mYPet plus mECFP*), with P<0.0001 (***) and P=0.0007 (**) (paired t test), respectively. For the co-transfections, the FRET efficiency of mYPet-hPCFT plus hPCFT-mECFP* is significantly higher than that of hPCFT-mYPet plus hPCFT-mECFP* (P=0.0003; paired t test). Panel D, Images collected in the FRET channel were calculated, as described under Experimental Procedures. Representative images for each sample are shown. Calculated FRET values for both test samples (mYPet-hPCFT plus hPCFT-mECFP*, and hPCFT-mYPet plus hPCFT-mECFP*) and controls (mYPet plus mECFP*, mYPetmECFP*) are represented using a pseudo color scale. NET FRET signals for both hPCFT samples were found mainly in the cell surface membranes, whereas significant FRET was observed intracellularly for the mYPet-mECFP* positive control. (30), an analogous reaction scheme is depicted for hPCFT-mediated transport which incorporates the functional impact of hPCFT oligomerization. The model starts from the outward-facing unloaded dimer, followed by the ordered binding of the co-transported protons (step 1) and (anti)folate substrates (step 2), which triggers a conformational change resulting in simultaneous transition of the two hPCFT monomers to an inward-facing state (step 3). This is followed by an ordered release of substrates (step 4) and then protons (step 5) into the cytoplasm. The unloaded homo-oligomeric unit then returns to the outward-facing state (step 6) to complete the transport cycle. In this model, the two hPCFT monomers are suggested to function cooperatively in facilitating substrate and proton binding, conformational changes, and substrate and proton release. Further details are in the text. 
